American Pharmaceutical Giant Pfizer Pharmaceutical Co., Ltd. (PFIZER) acquired the desire of British pharmaceutical giant Astrazeneca，It has not been eliminated because of the latter's rejection。

 

According to a report from London on May 2nd, Reuters，Pfizer said on the same day，The acquisition quotation of Astraikon has been raised to 63 billion pounds (about $ 106 billion)，I hope to become the basis for the merger of both parties to discuss mergers，It is also said that Astraikon is evaluating the proposal。

 

The offer is equivalent to £ 50 per share (about $ 84.47)。Earlier this week，Astrikon rejected Pfizer's offer on its valuation of $ 98.9 billion，Tightly £ 46.61 per share。

 

Reuters of the above Reuters report，Pfizer said，Astrikon said that he will make a reply after his board evaluating the latest acquisition proposal。According to Pfizer's offer，Aslekang's shareholder will receive 1.854 shares of the company's shares and £ 15.98 cash。

 

Yesterday Wall Street Journal reported，Restore negotiation means that the two parties may take a step in a goodwill acquisition transaction，But whether it can be reached in the end is still uncertain。

 

If Pfizer and Astrikon finally reached an M & A agreement，It will create the world's largest pharmaceutical company，The types of drugs sold by the company after the merger will cover the cancer、Most diseases including diabetes and heart disease。

 

but，The news came out yesterday evening，Astrikang's board of directors has rejected Pfizer's latest purchase price worth $ 106 billion，The board believes that Pfizer’s latest merger proposal is insufficient。

 

 

According to British stake online sports bettingM stake online sports betting& A regulations，Pfizer's latest proposal to submit official acquisitions on Astraon on May 26，Otherwise, it should be announced to give up the purchase intention。

 

I was rejected a week ago

 

April 28th, April 28th, a week ago，Pfizer confirmed that it is seeking mergers and acquisitions of Astraika。According to the announcement，April 26，Pfizer once again proposed the acquisition intention to Astrikang，But Astrikon believes that Pfizer's offer seriously underestimate its value and refuse to negotiate。

 

Pfizer also said，January 5 this year，It has proposed to acquire Astraikon for 58.8 billion pounds ($ 98.9 billion)，But the negotiation ended on January 14。According to the acquisition proposal in January，Pfizer plans to acquire Astraikon with cash plus stocks，The valuation of Astraikon is 46.61 pounds per share (about $ 76.62)，The premium at that time was about 30%。This news made Astrakon's stock price soared 15%after the opening of April 28，Newspaper 78.94 US dollars，Valuation exceeds 100 billion US dollars。

 

The acquisition intention issued by Pfizer，Astrikang issued a statement on April 28，CEO of Pfizer (CEO) Ian & Middot; Ianream (Ianream) in contact with Astraika，No specific proposal，& ldquo; There is no specific and attractive solution to propose before & rdquo;，I will not discuss with Pfizer on the acquisition problem。

 

Astrikan emphasized to shareholders in this statement，I have confidence in implementing Astraikon's strategy as a independent company，& ldquo; Strongly recommended & rdquo; Shareholders do not take action on Pfizer's approach。

 

Previous April 24，Chief Executive Pascalsoriot, CEO of Astraikon, expressed it when the company released a quarterly report，Strong and strong combination can sometimes achieve expected goals，but usually it is destructive，Another，For transactions like GSK (Glaxo Sonsk) and Novartis's business swap，Astrikang will also consider。

 

An senior person in a pharmaceutical company once analyzed the Morning Post reporter，Pfizer is the best company in pharmaceutical companies，Such a high -profile disclosure to the acquisition intention，Instructions will not give up this transaction easily，Maybe you may use & ldquo; hostile acquisition & rdquo; (Hostiletakeover，also known as forced acquisition)，Just like the acquisition of Warnerlambert;，At that time, the company's mergers and acquisitions negotiated with Wyeth were close to the end。

 

February 2000，Well & Middot; Langbert initially Stake Sports Bettingstake online sports bettingaccepted Pfizer's hostility，Acquisition is performed in the form of stock exchange，A $ 85 billion in funds，Pfizer after the merger becomes the largest pharmaceutical factory in the United States。In addition，2002，Pfizer acquired the Famasian Pharmaceutical Factory for $ 60 billion; in 2009, Pfizer acquired competitors Wyle，The total price of the transaction is about $ 68 billion。

 

Astrikang is the second largest pharmaceutical group in the UK，Digestion、Cardiovascular、central nervous nervous、Breathing、Tumor、Anesthesiology and anti -infection has several important diseases fields with multiple heavyweight prescription medicines。but，Because the company's patent of several best -selling drugs is about to expire，Its future growth prospects are full of variables。In the past three years，Astrikang's sales dropped from US $ 33.6 billion to $ 25.7 billion。Some analysts expect more drugs to lose patent protection，In the future, the company's loss will also expand。

 

If you successfully acquire Astraika，Pfizer's anti -cancer drug portfolio will be enhanced，and can save a lot of cost and tax burden。Pfizer will get experimental anti -cancer therapy，Also known as immunotherapy (by improving the body's immune system function to fight tumor)，The pharmaceutical industry believes that this will be the next mainstream of the market with rich profits。The aforementioned person said，Under the circumstance when a large number of heavy drugs expire，M & A for the supplementary value of Pfizer's product line is self -evident。Another point to note is，Acquisition can use a large amount of cash accumulated by Pfizer's subsidiaries outside the United States，These funds will be returned to the United States to be counted as heavy tax。

 

According to the data released by the research company Auditanalytics，Pfizer's overseas cash has reached 69 billion US dollars。

 

The above Wall Street Journal reports quoted the hint of Pfizer managers，Some cash reserves that the company earns and reserved abroad will be used to pay the funds required for the acquisition。

 

Pfizer lobby British government

 

Although Pfizer asked for asir with Astrakang，But this acquisition has caused political disputes in the UK，Because of this transaction, it is expected to become the largest case for British companies to be acquired by foreign companies。There is news，Some British lawmakers expressed their opposition to Pfizer's purchase proposal stake sports betting appStake Sports Bettingearlier this week，Instructed government departments must obtain Pfizer's guarantee for employment and research investment。

 

According to Reuters report，To reduce the concerns of the British government，Ian & Middot; Reed to British Prime Minister Cameron，Promise will complete the large -scale R & D center built in Cambridge, England，and keep it in a manufacturing plant in MacClesField。Ian & Middot; Reed also said，After the merger, the company will deploy 20%of R & D personnel in the UK。

 

Another news，Ian & Middot; Reed Meets with a number of British government ministers on April 29，Discuss possible acquisitions。He emphasized when meeting，The company plans to continue research and development and manufacturing in the UK，And will choose to register under the British tax system。

 

Wall Street Journal yesterday quoted Pfizer managers' words，Pfizer will put the registered company’s registration place in the UK，To reduce the company's tax rate。The manager also said，It is expected that the company will cut costs after merging。

 

The news came out last night，A spokesman for British Prime Minister Cameron said，Both companies, Britain and Pfizer and Astrikan, both keep in touch，and said that Pfizer's decision to acquire Astraikon is for business purposes。

 

It is worth mentioning that it is，Pfizer's acquisition plan，It may face antitrust censorship in China。Because，Pfizer and Astrikang's two companies in the prescription drug market in China，Locate the largest and second largest international supplier。

 

According to the sources quoted by Reuters, it is said，In addition to obtaining antitrust licenses from the United States and Europe, this merger and acquisition case，It must also pass the approval of China，It may be delayed because of this。Julianhuppert, a member of Cambridge City, British Cambridge City，China may be severely tried in this case，Especially in the scandal of the pharmaceutical company GlaxoSmithg in last year。

 

& ldquo; I know that China has doubts about this。From the perspective of China，This involves two major suppliers in the Chinese market as one，In view of the experience of contacting GlaxoSmiths in the past，There are indeed some obvious doubts。& rdquo; Huppert said to Reuters。

 

Currently for Pfizer，Get Astrakang's & ldquo; nod & rdquo;，is the key step of the acquisition。

 

Before the news of Astrikang's board of directors last night, the news that the board of directors had rejected the latest acquisition price，The point of view of the news quoted German Stake Sports Bettingsilver，The raising price stake online sports bettingis still not enough to ensure that the agreement is reached。

 

Deutsche's pointed out，The new price is about 7%higher than the acquisition price proposed in January，I believe Pfizer needs to increase cash as a price。Another，Investment company Panmuregordon said，The acquisition price of 50 pounds per share may attract investors，But the purchase price may be further increased to nearly 55 pounds per share。

 

Pfizer this huge acquisition plan，or it is expected to add a series of mergers and acquisitions for the global medical care industry this year。

 

Thomson Data Display，After a series of mergers and acquisitions appeared in the health care industry，The world's M & A transactions have exceeded $ 1 trillion in this year，For the third time since the compilation of the data has been compiled since 1980。M & A transactions that have occurred in the health care industry this year include: Zimmer proposed to acquire plastic surgery product manufacturers Biomet for $ 13.35 billion;，For more than 20 billion US dollars asset exchange。The trading that is happening includes: Germany Bayer seek to sell its plastic department worth $ 10 billion; the United States Merck desires to sell the consumer medical insurance department's business for $ 14 billion。